A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study

Head & Neck ◽  
2017 ◽  
Vol 39 (4) ◽  
pp. 767-771
Author(s):  
Joon-Hyop Lee ◽  
Yoo Seung Chung ◽  
Young Don Lee
2013 ◽  
Vol 38 (1) ◽  
pp. 68-79 ◽  
Author(s):  
Kenichi Matsuzu ◽  
Kiminori Sugino ◽  
Katsuhiko Masudo ◽  
Mitsuji Nagahama ◽  
Wataru Kitagawa ◽  
...  

2021 ◽  
Author(s):  
Abdul K. Siraj ◽  
Sandeep K. Parvathareddy ◽  
Zeeshan Qadri ◽  
Saud Azam ◽  
Felisa De Vera ◽  
...  

Thyroid ◽  
2019 ◽  
Vol 29 (6) ◽  
pp. 802-808 ◽  
Author(s):  
Wenwu Dong ◽  
Kiyomi Horiuchi ◽  
Hiroki Tokumitsu ◽  
Akiko Sakamoto ◽  
Eiichiro Noguchi ◽  
...  

2010 ◽  
Vol 95 (5) ◽  
pp. 2187-2194 ◽  
Author(s):  
Osama Al-Saif ◽  
William B. Farrar ◽  
Mark Bloomston ◽  
Kyle Porter ◽  
Matthew D. Ringel ◽  
...  

Abstract Objective: The objective of the study was to determine the outcome of surgical resection of metastatic papillary thyroid cancer (PTC) in cervical lymph nodes after failure of initial surgery and I131 therapy. Design: This was a retrospective clinical study. Setting: The study was conducted at a university-based tertiary cancer hospital. Patients: A cohort of 95 consecutive patients with recurrent/persistent PTC in the neck underwent initial reoperation during 1999–2005. All had previous thyroidectomy (±nodal dissection) and I131 therapy. Twenty-five patients with antithyroglobulin (Tg) antibodies were subsequently excluded. Main Outcome Measures: Biochemical complete remission (BCR) was stringently defined as undetectable TSH-stimulated serum Tg. Results: A total of 107 lymphadenectomies were undertaken in these 70 patients through January 2010. BCR was initially achieved in 12 patients (17%). Of the 58 patients with detectable postoperative Tg, 28 had a second reoperation and BCR was achieved in five (18%), seven had a third reoperation, and none achieved BCR. No patient achieving BCR had a subsequent recurrence after a mean follow-up of 60 months (range 4–116 months). In addition, two more patients achieved BCR during long-term follow-up without further intervention. In total, 19 patients (27%) achieved BCR and 32 patients (46%) achieved a TSH-stimulated Tg less than 2.0 ng/ml. Patients who did not achieve BCR had significant reduction in Tg after the first (P < 0.001) and second (P = 0.008) operations. No patient developed detectable distant metastases or died from PTC. Conclusions: Surgical resection of persistent PTC in cervical lymph nodes achieves BCR, when most stringently defined, in 27% of patients, sometimes requiring several surgeries. No biochemical or clinical recurrences occurred during follow-up. In patients who do not achieve BCR, Tg levels were significantly reduced. The long-term durability and impact of this intervention will require further investigation.


2014 ◽  
Vol 39 (4) ◽  
pp. 189-193 ◽  
Author(s):  
Mahdi Daliri ◽  
Mohammad Reza Abbaszadegan ◽  
Mostafa Mehrabi Bahar ◽  
Azadeh Arabi ◽  
Mona Yadollahi ◽  
...  

2019 ◽  
Vol 26 (6) ◽  
pp. 1737-1743 ◽  
Author(s):  
Amblessed E. Onuma ◽  
Eliza W. Beal ◽  
Fadi Nabhan ◽  
Tasha Hughes ◽  
William B. Farrar ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e16035-e16035
Author(s):  
William A. Wilson ◽  
Joseph Valentino ◽  
Thomas Gal ◽  
David Sloan ◽  
Kenneth B. Ain ◽  
...  

e16035 Background: Locoregionally recurrent radioactive iodine (RAI) refractory papillary thyroid cancer represents a small percentage of papillary thyroid cancers but is an aggressive disease with significantly lower survival rates. This retrospective review is our experience with these cancers treated with maximal surgical resection followed by external beam radiotherapy. Methods: 26 patients treated from 2001-2011 were eligible for review. After obtaining IRB approval, medical records were reviewed for clinical outcome. All patients had histologically proven recurrences that were negative on I-131 scans. All patients were maximally resected. All patients received external radiotherapy to the thyroid bed, bilateral cervical lymph node levels II-IV, level VI, and superior mediastinal nodes. 15/26 patients received intensity modulated, 9/26 patients received 3-D conformal, and 2/26 patients received Tomotherapy radiation treatment. The mean dose was 5790 cGy (range 5280-6800 cGy). Results: All histologies were papillary thyroid cancer with 4/26 exhibiting tall cell features and 1/26 diffuse sclerosing features. All patients had locoregional relapse in the cervical nodes (16/26) or in the mediastinum (5/26) or both areas (5/26). The mean pre-treatment thyroglobulin was 5.2 (range <0.1 to 599.1). The mean post-treatment thyroglobulin was 1.0 (range <0.1-5.2). Median follow-up was 55 months (range 7-123 months). 0/26 patients failed locoregionally. 2/26 patients failed distantly (lungs). 20/26 patients (77%) of patients had undetectable thyroglobulin at last follow-up. 4/26 patients had detectable thyroglobulin (2.5-16.9), but had not recurred on imaging. 2/26 required PEG placement during treatment, but 0/26 patients were PEG-dependent on long-term follow-up. 1/26 patients experienced grade III osteoradionecrosis of the mandible. Conclusions: External beam radiotherapy provides excellent locoregional control for locoregionally recurrent radioactive iodine-refractory papillary thyroid cancers. Long-term grade III and IV toxicities are uncommon.


2016 ◽  
Vol 223 (4) ◽  
pp. e97
Author(s):  
Eliza W. Beal ◽  
William B. Farrar ◽  
John E. Phay ◽  
Matthew D. Ringel ◽  
Richard T. Kloos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document